Cho, Soo Min Kim, Hyunjin Vincent Lee, Sejin Kim, Hye Yun Kim, Woong Kim, Tae Song Kim, Dong Jin Kim, YoungSoo 2024-01-20T08:33:31Z 2024-01-20T08:33:31Z 2022-01-10 2014-10-27 2045-2322 https://pubs.kist.re.kr/handle/201004/126220 Amyloid-beta (A beta) is one of the few neuropathological biomarkers associated with transporters of the blood-brain barrier (BBB). Despite the well-characterized clinical indication of decreasing A beta levels in the cerebrospinal fluid (CSF) during the development of Alzheimer's disease (AD), the link between the alternation of A beta level in the blood and the progress of the disorder is still controversial. Here, we report a direct correlation of A beta(1-42) levels between CSF and plasma in AD mouse model. We injected monomeric A beta(1-42) directly into the intracerebroventricular (ICV) region of normal adult mouse brains to induce AD-like phenotypes. Using sandwich enzyme-linked immunosorbent assays, we observed proportional elevation of A beta(1-42) levels in both CSF and plasma in a dose-dependent manner. Our findings that plasma A beta(1-42) reflects the condition of CSF A beta(1-42) warrant further investigation as a biomarker for the blood diagnosis of AD. English NATURE PUBLISHING GROUP COGNITIVE DECLINE DISEASE PROTEIN PEPTIDE CLEARANCE PREDICTOR DEMENTIA BRAIN MICE AGE Correlations of amyloid-beta concentrations between CSF and plasma in acute Alzheimer mouse model Article 10.1038/srep06777 1 SCIENTIFIC REPORTS, v.4 SCIENTIFIC REPORTS 4 scie scopus 000343978700009 2-s2.0-84945896478 Multidisciplinary Sciences Science & Technology - Other Topics Article COGNITIVE DECLINE DISEASE PROTEIN PEPTIDE CLEARANCE PREDICTOR DEMENTIA BRAIN MICE AGE 치매 알츠하이머병 진단 혈액 dementia Alzheimer diagnosis blood 개방형연구사업 ORP